Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHVNASDAQ:CDXSNASDAQ:FBIONASDAQ:SGMO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHVAchieve Life Sciences$3.49+4.5%$2.56$1.84▼$5.58$121.05M1.49194,615 shs527,627 shsCDXSCodexis$2.31-1.7%$2.37$1.90▼$6.08$191.37M2.56697,768 shs866,428 shsFBIOFortress Biotech$1.86-4.6%$1.65$1.33▼$2.89$55M1.85407,689 shs110,185 shsSGMOSangamo Therapeutics$0.45-1.5%$0.65$0.30▼$3.18$105.16M1.468.77 million shs4.19 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHVAchieve Life Sciences0.00%+14.80%+35.80%+22.46%-33.14%CDXSCodexis0.00%-3.75%-8.33%-15.38%-31.66%FBIOFortress Biotech0.00%+4.49%+1.64%+22.37%+1.09%SGMOSangamo Therapeutics0.00%-4.71%-38.07%-51.00%-20.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACHVAchieve Life Sciences1.9818 of 5 stars3.80.00.00.02.71.70.6CDXSCodexis3.6052 of 5 stars3.31.00.02.53.81.70.6FBIOFortress Biotech2.5409 of 5 stars3.51.00.00.02.83.30.6SGMOSangamo Therapeutics1.9567 of 5 stars3.31.00.00.02.50.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHVAchieve Life Sciences 3.50Strong Buy$14.33310.70% UpsideCDXSCodexis 2.67Moderate Buy$8.00246.32% UpsideFBIOFortress Biotech 3.00Buy$21.001,029.03% UpsideSGMOSangamo Therapeutics 2.67Moderate Buy$4.50897.78% UpsideCurrent Analyst Ratings BreakdownLatest FBIO, CDXS, SGMO, and ACHV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025SGMOSangamo TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$9.00 ➝ $5.004/7/2025SGMOSangamo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/18/2025SGMOSangamo TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$2.00 ➝ $2.003/11/2025FBIOFortress BiotechRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $16.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHVAchieve Life SciencesN/AN/AN/AN/A($0.07) per shareN/ACDXSCodexis$49.82M3.84N/AN/A$1.24 per share1.86FBIOFortress Biotech$57.78M0.95N/AN/A$0.10 per share18.60SGMOSangamo Therapeutics$63.76M1.65$0.01 per share30.42$0.47 per share0.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHVAchieve Life Sciences-$29.82M-$1.34N/AN/AN/AN/A-108.30%-65.20%8/12/2025 (Estimated)CDXSCodexis-$76.24M-$0.99N/AN/AN/A-96.35%-71.56%-38.00%8/7/2025 (Estimated)FBIOFortress Biotech-$60.64M-$2.23N/AN/AN/A-84.53%N/A-34.93%8/12/2025 (Estimated)SGMOSangamo Therapeutics-$257.83M-$0.39N/AN/AN/A-257.87%-264.16%-107.24%8/5/2025 (Estimated)Latest FBIO, CDXS, SGMO, and ACHV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025CDXSCodexis-$0.20-$0.25-$0.05-$0.25$10.38 million$7.54 million5/13/2025Q1 2025ACHVAchieve Life Sciences-$0.37-$0.37N/A-$0.37N/AN/A5/12/2025Q1 2025SGMOSangamo Therapeutics-$0.11-$0.14-$0.03-$0.14$7.90 million$6.44 million3/31/2025Q4 2024FBIOFortress Biotech-$0.79-$0.26+$0.53-$0.26$16.30 million$15.12 million3/17/2025Q4 2024SGMOSangamo Therapeutics-$0.09-$0.11-$0.02-$0.11$11.70 million$7.55 million3/11/2025Q4 2024ACHVAchieve Life Sciences-$0.30-$0.36-$0.06-$0.36N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHVAchieve Life SciencesN/AN/AN/AN/AN/ACDXSCodexisN/AN/AN/AN/AN/AFBIOFortress BiotechN/AN/AN/AN/AN/ASGMOSangamo TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHVAchieve Life Sciences0.316.786.78CDXSCodexis0.393.213.15FBIOFortress BiotechN/A1.231.06SGMOSangamo TherapeuticsN/A1.351.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHVAchieve Life Sciences33.52%CDXSCodexis78.54%FBIOFortress Biotech96.51%SGMOSangamo Therapeutics56.93%Insider OwnershipCompanyInsider OwnershipACHVAchieve Life Sciences2.00%CDXSCodexis2.10%FBIOFortress Biotech33.40%SGMOSangamo Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHVAchieve Life Sciences2034.69 million33.70 millionOptionableCDXSCodexis25082.85 million79.67 millionOptionableFBIOFortress Biotech17029.57 million18.39 millionOptionableSGMOSangamo Therapeutics480233.17 million202.81 millionOptionableFBIO, CDXS, SGMO, and ACHV HeadlinesRecent News About These CompaniesBrokerages Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Price Target at $4.50June 2 at 2:41 AM | americanbankingnews.comH.C. Wainwright Maintains Buy Rating on Sangamo Therapeutics (SGMO)May 31 at 7:12 PM | insidermonkey.comSangamo Therapeutics (NASDAQ:SGMO) Downgraded to "Sell" Rating by Wall Street ZenMay 31 at 2:49 AM | americanbankingnews.comSangamo Therapeutics (NASDAQ:SGMO) Lowered to "Sell" Rating by Wall Street ZenMay 31 at 2:08 AM | marketbeat.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Recommendation of "Moderate Buy" by AnalystsMay 31 at 1:09 AM | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Now Covered by Analysts at Wall Street ZenMay 24, 2025 | americanbankingnews.comStockNews.com Initiates Coverage on Sangamo Therapeutics (NASDAQ:SGMO)May 24, 2025 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Now Covered by StockNews.comMay 24, 2025 | marketbeat.comPoint72 Asset Management L.P. Takes $2.32 Million Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)May 23, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Decreases Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)May 20, 2025 | marketbeat.comHC Wainwright Has Optimistic Outlook of SGMO Q3 EarningsMay 20, 2025 | marketbeat.comStock Traders Buy High Volume of Sangamo Therapeutics Call Options (NASDAQ:SGMO)May 15, 2025 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Posts Earnings ResultsMay 14, 2025 | marketbeat.comSangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comSangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same DayMay 12, 2025 | finance.yahoo.comSangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue EstimatesMay 12, 2025 | zacks.comSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial ResultsMay 12, 2025 | businesswire.comSangamo Therapeutics Announces Pricing of $23.0 Million Underwritten OfferingMay 12, 2025 | businesswire.comSangamo Therapeutics Q1 2025 Earnings PreviewMay 12, 2025 | msn.comWhy Sangamo Therapeutics, Inc.’s (SGMO) Stock Is Up 5.70%May 10, 2025 | aaii.comSchonfeld Strategic Advisors LLC Purchases Shares of 1,709,615 Sangamo Therapeutics, Inc. (NASDAQ:SGMO)May 8, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFBIO, CDXS, SGMO, and ACHV Company DescriptionsAchieve Life Sciences NASDAQ:ACHV$3.49 +0.15 (+4.49%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$3.58 +0.09 (+2.58%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.Codexis NASDAQ:CDXS$2.31 -0.04 (-1.70%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$2.30 -0.01 (-0.43%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Fortress Biotech NASDAQ:FBIO$1.86 -0.09 (-4.62%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.89 +0.03 (+1.61%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Sangamo Therapeutics NASDAQ:SGMO$0.45 -0.01 (-1.46%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$0.46 +0.01 (+3.10%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
